The Presence of Nonnuclear Estrogen Receptor-alpha in Breast Cancer and Its Prognostic/Predictive Value

Abstract

There is rising biologic concern in breast cancer that the current standard purely measures nuclear ER expression, despite the fact that it is now widely accepted amongst scientists that ER signals non-genomically. The ultimate goal of this research is to develop one (or a variety of) assay(s) that can measure this non-genomic signaling and provide superior value in predicting response to Tamoxifen. My results to date have allowed me to develop a quantified and reproducible assay to measure nuclear ER, and use this assay to assess the rate and significance of misclassification in breast cancer patients today. We have also been able to detect non-nuclear ER in clinical samples, confirming that it is bona-fide ER, and that it appears to correlate with worse patient prognosis. We are also developing an assay to multiplex Src with full-length ER and determine whether this can provide additional prognostic or predictive value.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2009
Accession Number
ADA515798

Entities

People

  • Allison Welsh

Organizations

  • Yale University

Tags

DTIC Thesaurus Topics

  • Alkenes
  • Antibodies
  • Biomedical Research
  • Breast Cancer
  • Cell Line
  • Cells
  • Cultured Cells
  • Demographic Cohorts
  • Estrogens
  • Growth Factors
  • Hormones
  • Medical Personnel
  • Neoplasms
  • Physicians
  • Proteins
  • Standards
  • Tumor Cell Line

Fields of Study

  • Biology

Readers

  • Breast cancer cell signaling and growth regulation.
  • Oncology and Biomarker-Based Cancer Detection.
  • Strategic Security Studies